The gut microbiota metabolism of pomegranate or walnut ellagitannins yields two urolithin-metabotypes that correlate with cardiometabolic risk biomarkers: Comparison between normoweight, overweight-obesity and metabolic syndrome

Creative Commons License

Selma M. V., Gonzalez-Sarrias A., Salas-Salvado J., Andres-Lacueva C., Alasalvar C., ÖREM A., ...More

CLINICAL NUTRITION, vol.37, no.3, pp.897-905, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 37 Issue: 3
  • Publication Date: 2018
  • Doi Number: 10.1016/j.clnu.2017.03.012
  • Journal Name: CLINICAL NUTRITION
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.897-905
  • Keywords: Cardiovascular, Metabotype, Ellagic acid, Gut microbiota, Obesity, Polyphenols, ELLAGIC ACID METABOLISM, CARDIOVASCULAR-DISEASE, FOLLOW-UP, CONSUMPTION, GORDONIBACTER, ANTIOXIDANT, VARIABILITY, PHENOTYPES, DAIDZEIN, BLIND
  • Karadeniz Technical University Affiliated: Yes

Abstract

Background & aims: Urolithins are microbial metabolites produced after consumption of ellagitannin-containing foods such as pomegranates and walnuts. Parallel to isoflavone-metabolizing phenotypes, ellagitannin-metabolizing phenotypes (urolithin metabotypes A, B and 0; UM-A, UM-B and UM-0, respectively) can vary among individuals depending on their body mass index (BMI), but correlations between urolithin metabotypes (UMs) and cardiometabolic risk (CMR) factors are unexplored. We investigated the association between UMs and CMR factors in individuals with different BMI and health status.